Pharma & Biotech Global Week in Review 10 Nov 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

US government intervenes in patentability of genes – AMP v USPTO (Patent Baristas) (Holman’s Biotech IP Blog) (Intellectual Property Law Blog) (Inovia) (BlawgIT) (IP Osgoode)

Temodar (Temozolomide) – US: CAFC limits prosecution laches defense: Cancer Research Technology v Barr Laboratories (Inventive Step) (IPBiz) (Patently-O) (SmartBrief)

Italian antitrust authority opens preliminary investigation into whether Pfizer subsidiary artificially extended Latanoprost patent protection (PatLit)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

Global Fund calls upon drug companies to ‘share without delay’ AIDS drug patents with the Medicines Patent Pool (KEI)

Sharing US drug patents with neglected patients: A scientist’s view (IP Watch)

Statement of the United States to WTO TRIPS Council on the Paragraph 6 System (KEI)

Remarks by UNAIDS Secretariat and on behalf of UNDP: Capacity building on the Paragraph 6 System and related TRIPS flexibilities (KEI)

Seed patents and biodiversity (Patent Baristas)

BIO’s take on the CBD Nagoya Protocol (PatentlyBIOtech)

Australia: Gene patents back on the Australian political agenda (Patentology)

Brazil: Good growth in generic biz ahead (IP tango)

Brazil: Defending public health (IP tango)

European generic drug companies ask EU Parliament to remove patents from ACTA (KEI)

France: Cour d’Appel of Paris sides with Abbott in infringement case relating to patents related to HIV detection: Institut Pasteur v Abbott (EPLAW)

Taiwan: Fake medicines advertised on Taiwanese TV, radio and in newspapers (IP Dragon)

US: Abbott files reply brief in Therasense case (Patent Docs)

US: Panel discussion on Therasense v. Becton-Dickinson (Patent Docs)

US government intervenes in patentability of genes – AMP v USPTO (Patent Baristas) (Holman’s Biotech IP Blog) (Intellectual Property Law Blog) (Inovia) (BlawgIT) (IP Osgoode)

US: BIO and AUTM fire back at gene patent foes – AMP v USPTO (Patent Baristas) (Patent Docs)

US: IPO files amicus brief in AMP v USPTO (Patent Docs) (Patent Baristas)

US: AIPLA submits amicus brief in AMP v USPTO (Patent Docs)

US: Summary of Myriad patent claims under attack in AMP v PTO (Holman’s Biotech IP Blog)

US: Bayh-Dole patent ownership dispute to be heard by Supreme Court: Stanford v. Roche (Filewrapper) (Property, intangible)

US: Senator Sanders letter to FDA: U.S. needs an ethical pathway for biological products (KEI) (FDA Law Blog)

US: Daiichi Sankyo seeks review and correction of patent term adjustment calculation for patent relating to ‘nucleoside and oligonucleotide analogues’ (Patent Docs)

US: CAFC in Abraxis v Navinta: remembering Stanford/Roche (IPBiz)

Products

Alimta (Pemetrexed) – US: Eli Lilly files patent infringement complaint against Teva in response to Para IV certification filing (Patent Docs)

Amlodipine – Spain: Supreme Court puts end to long lasting proceedings over Amlodipine; finds infringement: Cinfa v Pfizer (EPLAW)

Boniva (Ibandronate) – US: Hoffman-La Roche files patent infringement complaint against Dr Reddys in response to Para IV certification (Patent Docs)

Colcrys (Colchicine) – US: Hikma Pharmaceuticals and Mutual Pharmaceutical settle patent suit over Colcrys (Patent Docs)

Crestor (Rosuvastatin) – US: Inherent property of earlier-made Crestor formulations invalidate later-issued Teva patent: Teva v Astrazeneca (Docket Report)

Enablex (Darifenacin) – US: Novartis and Watson end Enablex patent suit (Patent Docs)

Gemzar (Gemcitabine) – US: By slimmest of margins, Federal Circuit declines to rehear double patenting case: Sun Pharma. v Eli Lilly & Co (Orange Book Blog) (IPBiz)

PhosLo GelCaps (Calcium) – US: Fresenius Medical Care files patent infringement complaint against Lupin in response to Para IV certification (Patent Docs)

Plavix (Clopidogrel) – US: Sanofi and BMS awarded $442M in Plavix patent suit (Patent Docs)

Protopic (Tacrolimus) – US: Astella files patent infringement complaints against Nycomed in S D New York and New Jersey in response to Para IV filing (Patent Docs)

Pulmicort Respules (Budesonide) – US: CAFC affirmance of preliminary injunction: AstraZeneca v Apotex (Patently-O) (IPBiz)

Temodar (Temozolomide) – US: CAFC limits prosecution laches defense: Cancer Research Technology v Barr Laboratories (Inventive Step) (IPBiz) (Patently-O) (SmartBrief)

Viagra (Sildenafil) – US: Pfizer files patent infringement against Actavis, Apotex, Mylan, Amneal in response to Para IV certification (Patent Docs)

Welchol (Colesevelam) – US: Daiichi Sankyo and Genzyme file patent infringement suit against Lupin following its Para IV certification filing (Patent Docs)

Latanoprost – Italy: Antitrust authority opens preliminary investigation into whether Pfizer subsidiary has artificially extended Latanoprost patent protection (PatLit)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: